Citigroup’s Tvardi Therapeutics TVRD Stock Holding History

Citigroup’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-3	Closed	-$2K	–	7587
2020 Q4	$2K	Hold	3	–	–	﹤0.01%	7255
2020 Q3	$1K	Hold	3	–	–	﹤0.01%	7395
2020 Q2	$2K	Sell	3 -3	-50%	-$1.66K	﹤0.01%	7431
2020 Q1	$3K	Sell	6 -227	-97%	-$123K	﹤0.01%	7394
2019 Q4	$135K	Sell	233 -289	-55%	-$203K	﹤0.01%	5497
2019 Q3	$344K	Buy	522 +203	+64%	+$169K	﹤0.01%	4691
2019 Q2	$247K	Buy	319 +208	+187%	+$146K	﹤0.01%	5087
2019 Q1	$78K	Sell	111 -347	-76%	-$208K	﹤0.01%	5975
2018 Q4	$215K	Sell	458 -617	-57%	-$398K	﹤0.01%	4957
2018 Q3	$927K	Buy	1,075 +136	+14%	+$98.2K	﹤0.01%	3579
2018 Q2	$647K	Buy	939 +403	+75%	+$205K	﹤0.01%	3820
2018 Q1	$239K	Buy	536 +114	+27%	+$55.3K	﹤0.01%	4789
2017 Q4	$186K	Buy	422 +233	+123%	+$106K	﹤0.01%	5118
2017 Q3	$93K	Buy	+189	New	+$94.6K	﹤0.01%	5626

Other funds holding TVRD

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

AFG

American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SAM

Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

DWAM

Duncan Williams Asset Management Memphis, Tennessee $444M AUM 24.78% 1-Year Est. Return

Citigroup's TVRD Position: Q1 2026 in Review

Citigroup increased its Tvardi Therapeutics (TVRD) stake by 124% in Q1 2026, buying an estimated $599 and bringing the position to 276 shares worth $878. The position accounts for ﹤0.01% of the portfolio, ranked #5495.

Citigroup first reported a position in TVRD in Q2 2014 and has held it in 47 quarters since. The position peaked at $3.88M in Q4 2018. 67 funds tracked by Wall St. Rank hold TVRD as of Q1 2026.

Citigroup held 276 shares of Tvardi Therapeutics worth $878 as of Q1 2026.
Citigroup bought 153 Tvardi Therapeutics shares in Q1 2026, an estimated $599.
Tvardi Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #5495 holding.
Citigroup first reported a position in Tvardi Therapeutics in Q2 2014 and has held it in 47 quarters since.
Citigroup's Tvardi Therapeutics position peaked at $3.88M in Q4 2018.
67 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.